免疫疗法
免疫系统
黑色素瘤
生物
后天抵抗
癌症研究
癌症免疫疗法
计算生物学
免疫学
T细胞
癌症
获得性免疫系统
调节器
肿瘤进展
树突状细胞
调节性T细胞
封锁
肿瘤细胞
免疫检查点
抗原
免疫
免疫监视
细胞
PD-L1
机制(生物学)
细胞毒性T细胞
作者
Rachel S Sousa,Shannon N Geels,Claire Murat,Alexander Moshensky,Mauro Di Pilato,S. Armando Villalta,John Lowengrub,Francesco Marangoni
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2026-08-20
标识
DOI:10.1158/0008-5472.can-25-5784
摘要
The immune system can eradicate cancer, but various immunosuppressive mechanisms active within a tumor curb this beneficial response. However, unraveling the effects of multimodal interactions between tumor and immune cells and their contributions to tumor control using an experimental approach alone is time- and resource-intensive. To identify the critical immunological features associated with tumor control and escape, we built a mechanistic, structurally identifiable mathematical model of the interactions between CD8+ T cells, regulatory T cells (Tregs), dendritic cells, and tumor cells deeply rooted in current biological concepts. The model captured Treg accrual occurring after checkpoint blockade immunotherapy. After successfully fitting the mathematical model to experimental data from an immunogenic melanoma mouse model with acquired resistance to PD-1 immunotherapy and ensuring that the model was practically identifiable, hundreds of parameter sets were generated, each of which fit the data well and represented a unique 'virtual mouse' to capture variability across individuals. The model indicated that the initial tumor and immune conditions instruct cancer control or progression and that optimal initial ratios of immune cells exist that result in improved tumor control. The model further predicted that the Treg influx into the tumor is a key determinant of resistance to PD-1 immunotherapy. Experimental studies validated all these predictions from the model. Overall, this integrated approach of modeling and experimental validation identified crucial determinants of resistance to PD-1 immunotherapy and can be used to guide the development of more effective therapeutic strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI